The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
Open accessAbstract
The protein Keap1 is central to the regulation of the Nrf2-mediated cytoprotective response, and is increasingly recognized as an important target for therapeutic intervention in a range of diseases involving excessive oxidative stress and inflammation. The BTB domain of Keap1 plays key roles in sensing environmental electrophiles and in mediating interactions with the Cul3/Rbx1 E3 ubiquitin ligase system, and is believed to be the target for several small molecule covalent activators of the Nrf2 pathway. However, despite structural information being available for several BTB domains from related proteins, there have been no reported crystal structures of Keap1 BTB, and this has precluded a detailed understanding of its mechanism of action and interaction with antagonists. We report here the first structure of the BTB domain of Keap1, which is thought to contain the key cysteine residue responsible for interaction with electrophiles, as well as structures of the covalent complex with the antagonist CDDO/bardoxolone, and of the constitutively inactive C151W BTB mutant. In addition to providing the first structural confirmation of antagonist binding to Keap1 BTB, we also present biochemical evidence that adduction of Cys 151 by CDDO is capable of inhibiting the binding of Cul3 to Keap1, and discuss how this class of compound might exert Nrf2 activation through disruption of the BTB-Cul3 interface.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedBerman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Clustal W and Clustal X version 2.0
Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,358
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Scaling and assessment of data quality
Evans, P. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905036693 · Cited by 4,374
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Zhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480 · cited 1×
“Increased levels of oxidative or electrophilic stress have been shown to result in covalent modification of key cysteine residues in the BTB and BACK domains [3,15–21] leading to dissociation of Cul3, and potentially other conformational changes that cause loss of productive Nrf2 binding [1,22,23].”
BackgroundKeap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex
Zhang, D. D., Lo, S.-C., Cross, J. V., Templeton, D. J., & Hannink, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10941-10953.2004 · Cited by 1,254
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155 · cited 1×
“Other Keap1 antagonists include the naturally occurring isothiocyanate sulforaphane [41], and the compound Tecifidera (BG-12/dimethyl fumarate; Biogen Idec) which has recently been approved by the FDA for the treatment of multiple sclerosis, and believed to operate (at least in part) via Keap1-mediated activation of t…”
BackgroundGenetic ablation of Nrf2 enhances susceptibility to cigarette smoke–induced emphysema in mice
Rangasamy, T., Cho, C. Y., Thimmulappa, R. K., Zhen, L., Srisuma, S. S., Kensler, T. W., Yamamoto, M., Petrache, I., Tuder, R. M., & Biswal, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421146 · Cited by 991
Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986 · cited 2×
“Increased levels of oxidative or electrophilic stress have been shown to result in covalent modification of key cysteine residues in the BTB and BACK domains [3,15–21] leading to dissociation of Cul3, and potentially other conformational changes that cause loss of productive Nrf2 binding [1,22,23].”
BackgroundCullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8477-8486.2004 · Cited by 986
Kobayashi, A., Kang, M.-I., Watai, Y., Tong, K. I., Shibata, T., Uchida, K., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.221-229.2006 · Cited by 933
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Small Molecule Modulators of Keap1‐ Nrf2‐ ARE Pathway as Potential Preventive and Therapeutic Agents
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759
Functional antioxidant responsive elements
Wasserman, W. W., & Fahl, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5361 · Cited by 705
Sequence and structural analysis of BTB domain proteins
Stogios, P. J., Downs, G. S., Jauhal, J. J., Nandra, S. K., & Privé, G. G. (2005) · Genome Biology · doi:10.1186/gb-2005-6-10-r82 · Cited by 694 · cited 3×
“In common with related family members, it acts in concert with members of the CRL3 class of Cullin-RING-Ligase E3 ligases to provide substrate-specific recruitment for ubiquitination, and consists of a three domain architecture composed of an N-terminal BTB (Broad complex, Tramtrack, and Bric-a-Brac) domain, an interv…”
BackgroundSerine is a natural ligand and allosteric activator of pyruvate kinase M2
Chaneton, B., Hillmann, P., Zheng, L., Martin, A. C. L., Maddocks, O. D. K., Chokkathukalam, A., Coyle, J. E., Jankevics, A., Holding, F. P., Vousden, K. H., et al. (2012) · Nature · doi:10.1038/nature11540 · Cited by 661
Kobayashi, M., Li, L., Iwamoto, N., Nakajima-Takagi, Y., Kaneko, H., Nakayama, Y., Eguchi, M., Wada, Y., Kumagai, Y., & Yamamoto, M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01080-08 · Cited by 638
Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection
Zhang, M., An, C., Gao, Y., Leak, R. K., Chen, J., & Zhang, F. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.09.003 · Cited by 617
Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice
Rangasamy, T., Guo, J., Mitzner, W. A., Roman, J., Singh, A., Fryer, A. D., Yamamoto, M., Kensler, T. W., Tuder, R. M., Georas, S. N., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050538 · Cited by 580
Dinkova-Kostova, A. T., Liby, K. T., Stephenson, K. K., Holtzclaw, W. D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., Gribble, G. W., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500815102 · Cited by 569
LEVONEN, A.-L., LANDAR, A., RAMACHANDRAN, A., CEASER, E. K., DICKINSON, D. A., ZANONI, G., MORROW, J. D., & DARLEY-USMAR, V. M. (2004) · Biochemical Journal · doi:10.1042/bj20031049 · Cited by 560
Physiological Significance of Reactive Cysteine Residues of Keap1 in Determining Nrf2 Activity
Yamamoto, T., Suzuki, T., Kobayashi, A., Wakabayashi, J., Maher, J., Motohashi, H., & Yamamoto, M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01704-07 · Cited by 513
Zhuang, M., Calabrese, M. F., Liu, J., Waddell, M. B., Nourse, A., Hammel, M., Miller, D. J., Walden, H., Duda, D. M., Seyedin, S. N., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.022 · Cited by 486
Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism
Tong, K. I., Kobayashi, A., Katsuoka, F., & Yamamoto, M. (2006) · Biological Chemistry · doi:10.1515/bc.2006.164 · Cited by 473 · cited 3×
“Keap1 is known to dimerize through its BTB domain [12], and models of the mechanism of action require dimerization for constructive engagement with the Nrf2 substrate [13].”
BackgroundEggler, A. L., Liu, G., Pezzuto, J. M., van Breemen, R. B., & Mesecar, A. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502402102 · Cited by 456
McMahon, M., Lamont, D. J., Beattie, K. A., & Hayes, J. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007387107 · Cited by 443
Tong, K. I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., & Yamamoto, M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00753-07 · Cited by 442
The Nrf2/ARE Pathway as a Potential Therapeutic Target in Neurodegenerative Disease
Calkins, M. J., Johnson, D. A., Townsend, J. A., Vargas, M. R., Dowell, J. A., Williamson, T. P., Kraft, A. D., Lee, J.-M., Li, J., & Johnson, J. A. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2242 · Cited by 438
The cancer chemopreventive actions of phytochemicals derived from glucosinolates
Hayes, J. D., Kelleher, M. O., & Eggleston, I. M. (2008) · European Journal of Nutrition · doi:10.1007/s00394-008-2009-8 · Cited by 404
Hong, F., Freeman, M. L., & Liebler, D. C. (2005) · Chemical Research in Toxicology · doi:10.1021/tx0502138 · Cited by 404
The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm
Zipper, L. M., & Mulcahy, R. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206530200 · Cited by 366 · cited 1×
“Keap1 is known to dimerize through its BTB domain [12], and models of the mechanism of action require dimerization for constructive engagement with the Nrf2 substrate [13].”
BackgroundSussan, T. E., Rangasamy, T., Blake, D. J., Malhotra, D., El-Haddad, H., Bedja, D., Yates, M. S., Kombairaju, P., Yamamoto, M., Liby, K. T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804333106 · Cited by 346
Nrf2‐deficient mice are highly susceptible to cigarette smoke‐induced emphysema
Iizuka, T., Ishii, Y., Itoh, K., Kiwamoto, T., Kimura, T., Matsuno, Y., Morishima, Y., Hegab, A. E., Homma, S., Nomura, A., et al. (2005) · Genes to Cells · doi:10.1111/j.1365-2443.2005.00905.x · Cited by 336
Specific Patterns of Electrophile Adduction Trigger Keap1 Ubiquitination and Nrf2 Activation
Hong, F., Sekhar, K. R., Freeman, M. L., & Liebler, D. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503346200 · Cited by 317
Modification of Keap1 Cysteine Residues by Sulforaphane
Hu, C., Eggler, A. L., Mesecar, A. D., & van Breemen, R. B. (2011) · Chemical Research in Toxicology · doi:10.1021/tx100389r · Cited by 309
Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases
Canning, P., Cooper, C. D. O., Krojer, T., Murray, J. W., Pike, A. C. W., Chaikuad, A., Keates, T., Thangaratnarajah, C., Hojzan, V., Marsden, B. D., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.437996 · Cited by 284 · cited 5×
“Further experimental evidence is clearly required to distinguish between these and other possibilities, and a more complete understanding of the effects of Cys 151 perturbation might benefit from structural information for a construct containing at least the first ,50 residues of the BACK domain (the ‘‘3-box’’ motif),…”
BackgroundMethodInfluentialGao, L., Wang, J., Sekhar, K. R., Yin, H., Yared, N. F., Schneider, S. N., Sasi, S., Dalton, T. P., Anderson, M. E., Chan, J. Y., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607622200 · Cited by 277
Validation of the multiple sensor mechanism of the Keap1-Nrf2 system
Takaya, K., Suzuki, T., Motohashi, H., Onodera, K., Satomi, S., Kensler, T. W., & Yamamoto, M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.023 · Cited by 276
Honda, T., Rounds, B. V., Bore, L., Finlay, H. J., Favaloro, Suh, N., Wang, Y., Sporn, M. B., & Gribble, G. W. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002230 · Cited by 241 · cited 1×
“CDDO for the crystallographic work was prepared using literature procedures [57–60].”
MethodActivation of the Nrf2–ARE signaling pathway: a promising strategy in cancer prevention
Giudice, A., & Montella, M. (2006) · BioEssays · doi:10.1002/bies.20359 · Cited by 234
Ogura, T., Tong, K. I., Mio, K., Maruyama, Y., Kurokawa, H., Sato, C., & Yamamoto, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914036107 · Cited by 229
Rachakonda, G., Xiong, Y., Sekhar, K. R., Stamer, S. L., Liebler, D. C., & Freeman, M. L. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700302s · Cited by 207
Honda, T., Rounds, B. V., Gribble, G. W., Suh, N., Wang, Y., & Sporn, M. B. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00479-x · Cited by 204
Sites of alkylation of human Keap1 by natural chemoprevention agents
Luo, Y., Eggler, A. L., Liu, D., Liu, G., Mesecar, A. D., & van Breemen, R. B. (2007) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2007.09.015 · Cited by 190
Eggler, A. L., Small, E., Hannink, M., & Mesecar, A. D. (2009) · Biochemical Journal · doi:10.1042/bj20090471 · Cited by 176
Keap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171 · cited 2×
“A number of small molecule antagonists of Keap1 are known, the majority of which are electrophiles believed to function by covalent modification of the Keap1 cysteine residues responsible for sensing oxidative stress [35–39].”
BackgroundSelf-citationTargeting the Nrf2 pathway against cardiovascular disease
Li, J., Ichikawa, T., Janicki, J. S., & Cui, T. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903025762 · Cited by 171
Adaptor Protein Self-Assembly Drives the Control of a Cullin-RING Ubiquitin Ligase
Errington, W. J., Khan, M. Q., Bueler, S. A., Rubinstein, J. L., Chakrabartty, A., & Privé, G. G. (2012) · Structure · doi:10.1016/j.str.2012.04.009 · Cited by 150
AstexViewerTM †: a visualisation aid for structure-based drug design
Hartshorn, M. J. (2002) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1023813504011 · Cited by 145
Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
Saalau-Bethell, S. M., Woodhead, A., Chessari, G., Carr, M. G., Coyle, J. E., Graham, B. L., Hiscock, S. D., Murray, C. W., Pathuri, P., Rich, S. J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1081 · Cited by 120
Self-citationIchikawa, T., Li, J., Meyer, C. J., Janicki, J. S., Hannink, M., & Cui, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008391 · Cited by 99
Automated Protein–Ligand Crystallography for Structure‐Based Drug Design
Mooij, W. T. M., Hartshorn, M. J., Tickle, I. J., Sharff, A., Verdonk, M. L., & Jhoti, H. (2006) · ChemMedChem · doi:10.1002/cmdc.200600074 · Cited by 97
Self-citationProspective Type 1 and Type 2 Disulfides of Keap1 Protein
Holland, R., Hawkins, A., Eggler, A. L., Mesecar, A. D., Fabris, D., & Fishbein, J. C. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800226m · Cited by 97
Fragment Screening Using X-Ray Crystallography
Davies, T. G., & Tickle, I. J. (2011) · Topics in current chemistry · doi:10.1007/128_2011_179 · Cited by 82
Self-citationCrystal Structure of KLHL3 in Complex with Cullin3
Ji, A. X., & Privé, G. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060445 · Cited by 80
Eggler, A. L., Luo, Y., van Breemen, R. B., & Mesecar, A. D. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700217c · Cited by 80
Diffusion dynamics of the Keap1–Cullin3 interaction in single live cells
Baird, L., & Dinkova‐Kostova, A. T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.065 · Cited by 60
Honda, T., Janosik, T., Honda, Y., Han, J., Liby, K. T., Williams, C. R., Couch, R. D., Anderson, A. C., Sporn, M. B., & Gribble, G. W. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049727e · Cited by 56
Chemopreventive Promise of Targeting the Nrf2 Pathway
Yates, M. S., & Kensler, T. W. (2007) · Drug News & Perspectives · doi:10.1358/dnp.2007.20.2.1083437 · Cited by 53
Insights into Strand Exchange in BTB Domain Dimers from the Crystal Structures of FAZF and Miz1
Stogios, P. J., Cuesta-Seijo, J. A., Chen, L., Pomroy, N. C., & Privé, G. G. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.05.028 · Cited by 29
Cited by
Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy
Forman, H. J., & Zhang, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00233-1 · Cited by 2,900
The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis
Yamamoto, M., Kensler, T. W., & Motohashi, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2017 · Cited by 1,968
The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Baird, L., & Yamamoto, M. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00099-20 · Cited by 1,542
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease
Ngo, V., & Duennwald, M. L. (2022) · Antioxidants · doi:10.3390/antiox11122345 · Cited by 1,130
“The N-terminal BTB (broad complex, tramtrack, and bric à brac) domain mediates Keap1 homodimerization and contributes to its interaction with Cul3 [68].”
Background
Metadata
- Authors
- Cleasby, A., Yon, J., Day, P. J., Richardson, C., Tickle, I. J., Williams, P. A., Callahan, J. F., Carr, R., Concha, N., Kerns, J. K., Qi, H., Sweitzer, T., Ward, P., & Davies, T. G.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-06-04
- Volume
- 9
- Issue
- 6
- Pages
- e98896
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2160358010
- Cited by
- 258
- References
- 69
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.